PharmGKB summary: very important pharmacogene information for CYP2B6.
作者信息
Thorn Caroline F, Lamba Jatinder K, Lamba Vishal, Klein Teri E, Altman Russ B
机构信息
Department of Genetics, Stanford University Medical Center, Stanford, California 94305-5120, USA.
出版信息
Pharmacogenet Genomics. 2010 Aug;20(8):520-3. doi: 10.1097/fpc.0b013e32833947c2.
Abstract
摘要
相似文献
1
PharmGKB summary: very important pharmacogene information for CYP2B6.
Pharmacogenet Genomics. 2010 Aug;20(8):520-3. doi: 10.1097/fpc.0b013e32833947c2.
2
Absence of CYP2B6 promoter -82T>C mutation in Chinese as an additional factor for slow metabolism of drugs commonly used in infections.
Eur J Clin Pharmacol. 2006 Jul;62(7):585-6. doi: 10.1007/s00228-006-0163-6. Epub 2006 Jun 13.
3
PCR-based haplotype determination to distinguish CYP2B6*1/*7 and *5/*6.
Clin Chem. 2004 Aug;50(8):1472-3. doi: 10.1373/clinchem.2004.033233.
4
Detection of single nucleotide polymorphisms in CYP2B6 gene.
Methods Enzymol. 2002;357:45-53. doi: 10.1016/s0076-6879(02)57664-3.
5
Pharmacogenetic screening: HLA-B(*) 5701 vs. CYP2B6 G516T.
HIV Med. 2011 Apr;12(4):255-6. doi: 10.1111/j.1468-1293.2010.00870.x.
6
CYP2B6: inching towards personalized medicine.
J Postgrad Med. 2012 Oct-Dec;58(4):233-4. doi: 10.4103/0022-3859.105436.
7
Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring?
Eur J Clin Pharmacol. 2008 Apr;64(4):335-6. doi: 10.1007/s00228-007-0440-z. Epub 2008 Jan 11.
8
Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism.
Pharmacogenet Genomics. 2007 Dec;17(12):1007-15. doi: 10.1097/01.fpc.0000220560.59972.33.
9
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.
Pharmacogenet Genomics. 2013 Dec;23(12):721-8. doi: 10.1097/FPC.0b013e3283653b27.
10
Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.
Pharmacogenetics. 2004 Apr;14(4):225-38. doi: 10.1097/00008571-200404000-00002.
引用本文的文献
1
CYP2B6 genetic variation in cyclophosphamide metabolism and hemorrhagic cystitis in Fanconi anemia patients undergoing allogeneic hematopoietic cell transplantation: A descriptive genetic association study.
Medicine (Baltimore). 2025 Mar 21;104(12):e41937. doi: 10.1097/MD.0000000000041937.
2
Association between the CYP2B6 polymorphisms and nonnucleoside reverse transcriptase inhibitors drug-induced liver injury: a systematic review and meta-analysis.
Sci Rep. 2024 Nov 27;14(1):29511. doi: 10.1038/s41598-024-79965-0.
3
Opioid use disorder in pediatric populations: considerations for perioperative pain management and precision opioid analgesia.
Expert Rev Clin Pharmacol. 2024 May-Jun;17(5-6):455-465. doi: 10.1080/17512433.2024.2343915. Epub 2024 Apr 21.
4
Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation.
Front Immunol. 2022 Sep 23;13:1002959. doi: 10.3389/fimmu.2022.1002959. eCollection 2022.
5
Pharmacogenomics of Opioid Treatment for Pain Management.
Methods Mol Biol. 2022;2547:491-504. doi: 10.1007/978-1-0716-2573-6_17.
6
Constitutive androstane receptor and pregnane X receptor genotype influence efavirenz plasma concentration and CYP2B6 enzyme activity.
Sci Rep. 2022 Jun 11;12(1):9698. doi: 10.1038/s41598-022-14032-0.
7
Impact of the novel CYP2C:TG haplotype and CYP2B6 variants on sertraline exposure in a large patient population.
Clin Transl Sci. 2022 Sep;15(9):2135-2145. doi: 10.1111/cts.13347. Epub 2022 Jun 22.
8
Pharmacogenetic distinction of the Croatian population from the European average.
Croat Med J. 2022 Apr 30;63(2):117-125. doi: 10.3325/cmj.2022.63.117.
9
CYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populations-Implication for Drug Safety, Dosing, and Individualized Therapy.
Front Genet. 2021 Jul 12;12:692234. doi: 10.3389/fgene.2021.692234. eCollection 2021.
10
Novel associations between polymorphisms, perioperative methadone metabolism and clinical outcomes in children.
Pharmacogenomics. 2021 Jul;22(10):591-602. doi: 10.2217/pgs-2021-0039. Epub 2021 Jun 8.
本文引用的文献
1
Pharmacokinetics of plasma efavirenz and CYP2B6 polymorphism in southern Chinese.
Ther Drug Monit. 2009 Aug;31(4):527-30. doi: 10.1097/FTD.0b013e3181ad74a4.
2
Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children.
Antivir Ther. 2009;14(3):315-20.
3
Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans.
J Infect Dis. 2009 Mar 15;199(6):872-80. doi: 10.1086/597125.
4
Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.
Br J Clin Pharmacol. 2009 Jan;67(1):50-60. doi: 10.1111/j.1365-2125.2008.03321.x. Epub 2008 Nov 17.
5
Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia.
Leukemia. 2009 Mar;23(3):545-56. doi: 10.1038/leu.2008.323. Epub 2008 Nov 13.
6
7
CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.
Curr Drug Metab. 2008 Sep;9(7):598-610. doi: 10.2174/138920008785821710.
8
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation.
Anal Bioanal Chem. 2008 Nov;392(6):1093-108. doi: 10.1007/s00216-008-2291-6. Epub 2008 Aug 10.
9
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.
J Antimicrob Chemother. 2008 Apr;61(4):914-8. doi: 10.1093/jac/dkn029. Epub 2008 Feb 14.
10
Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver.
J Pharmacol Exp Ther. 2008 Apr;325(1):284-92. doi: 10.1124/jpet.107.133306. Epub 2008 Jan 2.
Zotero 插件